10.1 Research Methodology & Biostatistics

Research Methodology & Biostatistics

Understanding research methodology and biostatistics is paramount for clinical pharmacists to properly evaluate literature and apply evidence to patient care. This section breaks down study designs, variable types, appropriate statistical testing, and clinical risk calculations necessary for the BCPS exam.

Study Designs

Clinical studies are broadly categorized into observational and experimental designs. The level of evidence varies significantly depending on the design, with meta-analyses and systematic reviews of randomized controlled trials (RCTs) sitting at the peak of the evidence hierarchy.

Observational Studies

Observational studies do not involve an intervention by the investigator. They are crucial for generating hypotheses and establishing associations, but they cannot definitively prove causation.

1. Case-Control Studies: These are always retrospective. Investigators identify patients with a specific outcome (cases) and without the outcome (controls), and look back in time to ascertain exposure to a risk factor. They are highly efficient for studying rare diseases. The statistical measure of association is the Odds Ratio (OR).
2. Cohort Studies: These can be prospective or retrospective. Investigators identify a cohort of patients based on their exposure status (exposed vs. unexposed) and follow them to see if they develop the outcome of interest. Cohort studies are optimal for studying rare exposures and establishing incidence. The measure of association is the Relative Risk (RR).
3. Cross-Sectional Studies: These evaluate prevalence at a single point in time. They cannot establish a temporal relationship between exposure and outcome.

Experimental Studies

1. Randomized Controlled Trials (RCTs): The gold standard for evaluating efficacy and safety. Randomization minimizes selection bias and evenly distributes both known and unknown confounders. RCTs establish causation.
2. Crossover Studies: Each participant serves as their own control, receiving both the intervention and control treatments separated by a washout period. This design reduces variance but is susceptible to carry-over effects and is only appropriate for chronic, stable conditions.

Biostatistics: Variable Types and Statistical Testing

Selecting the correct statistical test hinges primarily on the type of data (variable) being analyzed and whether the data meets the assumptions for parametric testing (e.g., normal distribution, equal variance).

Types of Variables

• Continuous Data: Data that can take any value within a range. Subdivided into interval (no absolute zero, e.g., Celsius temperature) and ratio (has an absolute zero, e.g., heart rate, blood pressure, weight).
• Discrete Data: Data that can only take specific values. Subdivided into nominal (categories with no inherent order, e.g., gender, mortality, marital status) and ordinal (categories with a ranked order but unequal intervals, e.g., NYHA Heart Failure Class, pain scales).

Selecting the Appropriate Statistical Test

Parametric Tests

Used for continuous data that is normally distributed (Gaussian distribution).

Non-Parametric Tests

Used for continuous data not normally distributed, or for discrete (nominal/ordinal) data.

Clinical Risk Calculations

Interpreting the clinical impact of an intervention requires calculating risk reductions and the number needed to treat/harm. In the equations below, Experimental Event Rate (EER) is the risk in the intervention group, and Control Event Rate (CER) is the risk in the control group.

Relative Risk (RR) and Relative Risk Reduction (RRR)

• Relative Risk (RR): The ratio of the probability of an outcome in an exposed group to the probability in an unexposed group.
  • $RR = \frac{EER}{CER}$
  • If RR < 1, the intervention reduces the risk. If RR > 1, the intervention increases the risk. If RR = 1, there is no difference.
• Relative Risk Reduction (RRR): The proportion of risk reduction achieved by the intervention compared to the control.
  • $RRR = 1 - RR$ or $\frac{CER - EER}{CER}$

Absolute Risk Reduction (ARR)

• Absolute Risk Reduction (ARR): The arithmetic difference in event rates between the control and experimental groups. ARR is more clinically meaningful than RRR because it accounts for the baseline risk of the disease.
  • $ARR = CER - EER$

Number Needed to Treat (NNT) and Harm (NNH)

• Number Needed to Treat (NNT): The number of patients who need to receive the intervention for a specific period to prevent one additional adverse event.
  • $NNT = \frac{1}{ARR}$ (expressed as a decimal, e.g., $\frac{1}{0.05}$)
  • Crucial Rule: Always round NNT UP to the next whole number. You cannot treat a fraction of a patient, and rounding up ensures a conservative estimate of benefit.
• Number Needed to Harm (NNH): The number of patients who need to receive the intervention to cause one additional adverse event (Absolute Risk Increase or ARI).
  • $ARI = EER - CER$
  • $NNH = \frac{1}{ARI}$
  • Crucial Rule: Always round NNH DOWN to the next whole number. This provides a conservative (worst-case) estimate of harm.

Odds Ratio (OR) and Hazard Ratio (HR)

• Odds Ratio (OR): Used in case-control studies. It is the odds of exposure among cases divided by the odds of exposure among controls.
• Hazard Ratio (HR): Used in survival analysis (time-to-event data). It represents the chance of an event occurring in the treatment arm divided by the chance in the control arm at any given time point. An HR < 1 indicates a protective effect.

Understanding these formulas and how to apply them to clinical scenarios is a high-yield competency for the BCPS examination. Mastery of biostatistics empowers the pharmacist to look beyond the author's conclusions and objectively evaluate the actual data presented in clinical literature.